BTIG analyst Ryan Zimmerman upgrades $Integra Lifesciences (IART.US)$ to a hold rating, and maintains the target price at $20.
According to TipRanks data, the analyst has a success rate of 43.8% and a total average return of 1.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Integra Lifesciences (IART.US)$'s main analysts recently are as follows:
Integra LifeSciences has faced persistent operational challenges over the past two years that have been difficult to surmount. A stabilization of the business is necessary to regain investor trust. The company is perceived to persist in establishing hopeful expectations that afford minimal margin for error. Concerns linger that Integra may have set its forecasts for Q4 and the year 2025 at levels that could be overly ambitious.
The valuation of Integra LifeSciences has reached a level where significant downside appears unlikely, according to an analyst. Near-term pressure on the shares might persist due to tax-loss selling as the year concludes, but the stock is beginning to attract the interest of deep value investors.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
BTIG分析師Ryan Zimmerman上調$英特格拉生命科學 (IART.US)$至持有評級，維持目標價20美元。
根據TipRanks數據顯示，該分析師近一年總勝率為43.8%，總平均回報率為1.8%。
此外，綜合報道，$英特格拉生命科學 (IART.US)$近期主要分析師觀點如下：
在過去的兩年中，Integra LifeSciences一直面臨着難以克服的持續運營挑戰。爲了重新獲得投資者的信任，業務的穩定是必要的。人們認爲，該公司堅持建立充滿希望的預期，將誤差餘地降至最低。人們仍然擔心Integra可能將其對第四季度和2025年的預測設定在過於雄心勃勃的水平。
一位分析師表示，Integra LifeSciences的估值已達到似乎不太可能出現重大下跌的水平。隨着年底，由於減稅拋售，股票的短期壓力可能會持續存在，但該股已開始吸引深度價值投資者的興趣。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
